A detailed history of Cetera Investment Advisers transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 52,711 shares of TGTX stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,711
Previous 53,425 1.34%
Holding current value
$1.7 Million
Previous $950,000 29.68%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$17.21 - $25.28 $12,287 - $18,049
-714 Reduced 1.34%
52,711 $1.23 Million
Q2 2024

Aug 22, 2024

SELL
$13.32 - $19.19 $128,564 - $185,221
-9,652 Reduced 15.3%
53,425 $950,000
Q1 2024

May 24, 2024

BUY
$13.02 - $21.3 $821,262 - $1.34 Million
63,077 New
63,077 $959,000
Q4 2023

Feb 13, 2024

SELL
$6.68 - $18.81 $46,873 - $131,989
-7,017 Reduced 16.17%
36,384 $621,000
Q3 2023

Nov 14, 2023

BUY
$8.36 - $26.5 $22,020 - $69,801
2,634 Added 6.46%
43,401 $362,000
Q2 2023

Aug 09, 2023

BUY
$15.48 - $35.0 $55,619 - $125,755
3,593 Added 9.67%
40,767 $1.01 Million
Q1 2023

May 15, 2023

BUY
$10.23 - $19.34 $190,329 - $359,820
18,605 Added 100.19%
37,174 $559,000
Q4 2022

Feb 14, 2023

SELL
$5.01 - $11.83 $1,277 - $3,016
-255 Reduced 1.35%
18,569 $219,000
Q3 2022

Nov 10, 2022

BUY
$4.57 - $8.4 $914 - $1,680
200 Added 1.07%
18,824 $111,000
Q2 2022

Aug 11, 2022

BUY
$3.74 - $10.66 $4,903 - $13,975
1,311 Added 7.57%
18,624 $79,000
Q1 2022

May 13, 2022

SELL
$7.81 - $20.45 $33,942 - $88,875
-4,346 Reduced 20.07%
17,313 $165,000
Q4 2021

Feb 14, 2022

BUY
$15.2 - $35.51 $44,292 - $103,476
2,914 Added 15.55%
21,659 $412,000
Q3 2021

Nov 16, 2021

BUY
$21.78 - $40.45 $136,037 - $252,650
6,246 Added 49.97%
18,745 $624,000
Q2 2021

Aug 13, 2021

BUY
$32.5 - $48.96 $406,217 - $611,951
12,499 New
12,499 $485,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.69B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.